HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
Apeloa and Simcere Partner for CDMO Services and R&D Collaboration
China – based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739)...
Sino Biopharmaceutical’s CTTQ Partners with ProteLight for Antibacterial Peptide PL-5
China – based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia...
Inscinstech Raises RMB 150 Million in Series A+, B, and B+ Rounds
Inscinstech Inc., a leading specialist in biological separation technology based in Suzhou, China, has successfully...
Everest Medicines Outlines Strategic Plans for Expansion and Growth
China – based biopharmaceutical company Everest Medicines (HKG: 1952) has announced its strategic plans for...
Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
China – based Jiangxi Jemincare Group has announced that it has received approval from the...
Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...
Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...
Guangdong Raynovent Biotech Secures RMB 370 Million in Series C Financing
Guangdong Raynovent Biotech Co., Ltd, a controlling subsidiary of China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd...
Hengrui Pharmaceuticals Appoints Dr. Jiang Ningjun as Deputy General Manager and CSO
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced the appointment of Dr. “Frank” Jiang Ningjun...
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for...
BeiGene’s Tislelizumab Receives NMPA Review for First-Line HCC Indication
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that a supplementary Biologic License Application...
Immunohead Biotech Raises RMB 200 Million in Series A+ Financing Round
Immunohead Biotechnology Co., Ltd, a cell therapy developer based in Suzhou, has reportedly raised close...
Biocytogen and Hansoh Enter Antibody Collaboration and Licensing Agreement
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced an antibody collaboration, assignment, and exclusive license...
CStone Pharmaceuticals Achieves Primary Endpoint in GEMSTONE-304 Study for Sugemalimab
China-based CStone Pharmaceuticals (HKG: 2616) has announced the achievement of the primary endpoint in the...
3D Medicines Gains FDA Approval for Phase II Study of Envafolimab in dMMR Tumors
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving approval from the US FDA...
Changzhou Qianhong Completes Phase I Study of QHRD107 for Acute Myeloid Leukemia
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced the completion of enrollment and...
Guangdong Zhongsheng Completes Enrollment for RAY1216 Phase III Study in COVID-19
China – based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the completion of...